Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.32 |
| ▸ | CCKBR | P32239 | 5/20 | 0.32 |
| ▸ | CCKAR | P32238 | 5/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29554598 | 0.92 | REN (0.37) | RENOPRD1CCKBRCCKARCTSS | |
| SCHEMBL31088668 | 0.90 | REN (0.36) | RENOPRD1CCKBRCCKARCTSS | |
| SCHEMBL29555524 | 0.86 | OPRD1 (0.41) | RENOPRD1CCKBRCCKAR | |
| SCHEMBL30096878 | 0.82 | REN (0.37) | RENOPRD1CCKBRCCKARCTSS | |
| SCHEMBL31094172 | 0.81 | NMBR (0.38) | RENBCHEACHE | |
| SCHEMBL29555339 | 0.81 | OPRM1 (0.39) | OPRD1CCKBRCCKAR | |
| SCHEMBL29824489 | 0.80 | OPRD1 (0.37) | RENOPRD1CCKBRCCKAR | |
| SCHEMBL34463366 | 0.79 | REN (0.38) | RENOPRD1CCKBRCCKAR | |
| SCHEMBL30437952 | 0.79 | REN (0.40) | RENOPRD1CCKBRCCKAR | |
| SCHEMBL30836804 | 0.78 | REN (0.42) | RENOPRD1CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | GLP1R, GCGR, GIPR | REN 713/4885OPRD1 2819/4885CCKBR 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.